Skip to main content

Richard
E.
Chaisson
,
MD

Professor
Richard Chaisson

Departmental Affiliations

School of Medicine
Primary
Joint
Division
Infectious Disease Epidemiology
Joint
Division
Global Disease Epidemiology and Control

Contact Info

1550 Orleans Street, Room 108
Baltimore
Maryland
21231
US        
410-955-0740

Research Interests

Tuberculosis; HIV; Infectious Diseases
Experiences & Accomplishments
Education
MD
Overview
Richard E. Chaisson, M.D., is Professor of Medicine, Epidemiology, and International Health and Director of the Johns Hopkins University Center for Tuberculosis Research and Principal Investigator of the Hopkins Center for AIDS Research (CFAR). The Center for Tuberculosis Research is a multidisciplinary research and training center for the study of TB from bench to bedside.  The CFAR is a multidisciplinary, university-wide program to promote HIV research, support new investigators, and address the Baltimore HIV epidemic.
Dr. Chaisson's research interests focus on tuberculosis and HIV infection, including global epidemiology and control, prevention, clinical trials, and public health interventions. He was principal investigator of the Consortium to Respond Effectively to the AIDS/TB Epidemic (CREATE), an international research consortium funded by the Bill and Melinda Gates Foundation to assess the impact of novel strategies for controlling HIV-related TB. He is a leader in the Tuberculosis Clinical Trials Consortium and the AIDS Clinical Trials Group's TB Transformative Science Group, and leads a number of trials funded by the CDC, NIH, and Unitaid. He has mentored >40 trainees during his career. He has published over 500 scientific papers and book chapters, and co-edited The Handbook of Tuberculosis with Jacques Grosset.
Honors & Awards
World Lung Health Award, American Thoracic Society, 2006
MD Dept Health & Mental Hygiene David Glasser Award, 2008
CDC Charles C. Shepard Award, 2012
USAID Champions of TB Control Award (for CREATE), 2014
Scientific Award, International Union Against Tuberculosis and Lung Disease, 2014
Association of American Professors, 2016
Fellow, American College of Physicians, 2016
Mentee-Mentor Award for Clinical Research, JHUSOM Office of Postdoctoral Affairs, 2017
Select Publications
Selected publications.
  • Sterling TR, Villarino ME, Borisov AS, Shang N, Gordin F, Bliven-Sizemore E, Hackman J, Hamilton CD, Menzies D, Kerrigan A, Weis SE, Weiner M, Wing D, Conde MB, Bozeman L, Horsburgh CR Jr, Chaisson RE; TB Trials Consortium PREVENT TB Study Team. Three months of rifapentine and isoniazid for latent tuberculosis infection.  N Engl J Med. 2011;365:2155-66.
  • Martinson NA, Barnes GL, Moulton LH, Msandiwa R, Hausler H, Ram M, McIntyre JA, Gray GE, Chaisson RE.  New regimens to prevent tuberculosis in adults with HIV infection.  N Engl J Med 2011;365:11-20. PMCID: PMC3407678
  • Dowdy DW, Golub JE, Chaisson RE, Saraceni V. Heterogeneity in tuberculosis transmission and the role of geographic hotspots in propagating epidemics.  Proc Natl Acad Sci U S A. 2012;109:9557-62
  • Durovni B, Saraceni V, Moulton LM, Pacheco AG, Cavalcante SC, King BS, Cohn S, Efron A, Chaisson RE, Golub JE.  Effect of improved tuberculosis screening and isoniazid preventive therapy on incidence of tuberculosis and death in patients with HIV in clinics in Rio de Janeiro, Brazil: a stepped wedge, cluster-randomised trial. Lancet Infect Dis. 2013;10:852-8
  • Rangaka MX, Cavalcante SC, Martinson N, Marais BJ, Thim S, Swaminathan S, Chaisson RE. Controlling the seedbeds of tuberculosis: diagnosis and treatment of tuberculosis infection. Lancet, 2015;386:2244-53.
Projects
ABC Training Grant For Rio De Janeiro ICDR
ZAMSTAR: Zambia and South Africa tuberculosis and AIDS reduction study. A study of the Consortium To Respond Effectively To the AIDS/TB Epidemic (CREATE).
Effect of community-wide isoniazid preventive therapy on tuberculosis among South African gold miners. A project of Consortium to Respond Effectively to the AIDS-TB Epidemic (CREATE)
Clinical Research in Tuberculosis
Novel TB Prevention Regimens for HIV-Infected Adults
Evaluation of a Moxifloxacin-Based, Isoniazid-Sparing Regimen for Tuberculosis Treatment, TBTC Study 28
Tuberculosis among the Tibetan Population in Dharamsala, India: TB Program Evaluation and Needs Assessment
A Tuberculosis Prevalence Survey in Western Kenya
Cluster randomized intervention trial to evaluate ‘opting-out’ vs. ‘opting-in’ strategies on the uptake of HIV counseling and testing of TB patients in the Province of the Eastern Cape, South Africa
A Randomized Trial of Novel TB Preventive Regimens for HIV-Infected Adults in Soweto, South Africa
A Multi-center Study of the MODS Test for Diagnosis of Pulmonary TB and TB Drug Resistance, Brazil
Multicenter Study of TK Medium for Rapid Detection of M. Tuberculosis (Brazil and South Africa)
Novel TB Preventive Regimens for HIV-Infected Adults in Soweto, South Africa
Evaluation of an Algorithm for the Diagnosis of Smear-Negative Tuberculosis in High HIV Prevalence Settings
Peer and Family-Based Social Support For HIV Treatment Adherence in South Africa
Whole Blood Cytokine Assay, South Africa
A Case-Control Study Investigating the Intersection Between Tobacco Use, Tuberculosis and HIV-infection
Longitudinal Study of HIV-Associated Lung Infections in Soweto
South African Tb/AIDS Training
TBTC Tuberculosis Trial Consortium
CDC Tuberculosis Trials Consortium
Impact of a New Molecular TB Test on TB/HIV Outcomes among HIV-Infected Malawians
Phase II Comprehensive ICHORTA AID
Chepetsa TB - Evaluation of a Molecular Diagnostic Test for TB in HIV Patients in Malawi
Tuberculosis Transformative Science Group, AIDS Clinical Trials Group
Statins as Adjunctive Therapy for Tuberculosis (StAT-TB)
Ultra Curto TB